enVVeno Medical Corp(NVNO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -25.04 | Insider Own | 8.01% | Shs Outstand | 0.7M | Perf Week | -1.59% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | -0.5% | Shs Float | 0.6M | Perf Month | -0.04% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -3.27 | Inst Own | 12.77% | Short Float | 3.81% | Perf Quarter | 8.28% |
| Income | -0.02B | P/S | - | EPS this Y | - | Inst Trans | -15.38% | Short Ratio | 1.36 | Perf Half Y | -9.81% |
| Sales | 0.00B | P/B | 0.36 | EPS next 5Y | 48.08% | ROA | -53.09% | Short Interest | 0.02M | Perf YTD | -0.96% |
| Book/sh | 30.71 | P/C | 0.36 | EPS past 3/5Y | 24.52% 34% | ROE | -58.53% | 52W High | -68.85% ($35.70) | Perf Year | -55.87% |
| Cash/sh | 30.94 | P/FCF | - | Sales past 3/5Y | - | ROIC | -75.69% | 52W Low | 28.26% ($8.67) | Perf 3Y | -94.15% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 43.06% | Gross Margin | - | Volatility(W/M) | 4.69% 7.91% | Perf 5Y | -96.33% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.78 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 11.7 | EPS Q/Q | 53.4% | Profit Margin | - | RSI (14) | 51.5 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 11.7 | Sales Q/Q | - | SMA20 | 0.89% ($11.02) | Beta | 1.26 | Target Price | $30 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/7/31 | SMA50 | 2.55% ($10.84) | Rel Volume | 3.4 | Prev Close | $11.1 |
| Employees | 33 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -14.5% - | SMA200 | 0.8% ($11.03) | Avg Volume(3M) | 0.02M | Price | $11.12 |
| IPO | 2018/5/31 | Option/Short | No/Yes | Trades | 542 | Volume | 60,936 | Change | 0.18% |
Company
NVNO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🫀 This is a small, early clinical/commercial-stage medical device company developing the <b>surgical prosthetic venous valve (VenoValve®)</b> and the next-generation transcatheter valve (enVVe), both targeting chronic venous insufficiency (CVI) of the deep veins. The company has received the FDA’s Breakthrough Device designation, but in August 2025 it was issued a not-approvable letter for the VenoValve PMA review, placing it in a restructuring phase.
Over the past 1 year, on the lower side
69% below its 1-year high.
NVNO has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +48.1% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -94.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 12.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $8M.
NVNO $8M PER -
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is NVNO?
NVNO belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of NVNO?
The market cap of NVNO is approximately $8M, ranking 5,578 within its sector.
What is the 52-week high and low for NVNO?
NVNO has recorded a 52-week high of $35.70 and a low of $8.67.
